Hubert J.P. Schoemaker and William T. McCormick. Perhaps we could have not a special day, but just a moment to remember what we owe and who we we owe it to.

Eisai plans $105-million plant. Novartis to build plant in China. BMS building $660-million biologics facility. Slow adoption of RFID. Vaccines update. $14.7 billion in pharma construction in 2006. Chiron sells Betaseron to Schering. Baxter to develop cell based H5N1 vaccine. Drug sales up 5.4%, but growth slowing.

Despite worries that industry is slow to adopt anticounterfeiting technologies, the 2006 Interphex program is rife with new methods for securing the supply chain.

Senior management must be the champions of change in companies that are struggling financially or organizationally.

Vitamin D and a sunny window shed som light on product stability.

No one is better than Europe when it comes to innovative products at the forefront of the industry

The right choice [of coding and marking technology] depends upon the company's top priorities regarding legibility, cost, speed, ease of use, cleanliness and security.

Once the brightest students are interested in bioprocessing, it is vital that they are prepared and inducted into industry.

Global Pharmaceutical Market Shows Moderate Growth

New Biodegradable Polyketals Developed for Drug Delivery

India and China Position for Growth in APIs

Progress Continues in Vaccine and Antiviral Development

GSK Begins RFID Pilot Program

Industry Leaders Call for New Paradigm in Drug Development

First GenerationNext Awards at Interphex 2006

BMS, Sanofi-Aventis Settle Over Generic Plavix

Spotlight on Products from Interphex

Actavis Makes $1.6 Billion Takevoer Bid for Pliva

Implementing a PAT Strategy

US Government Increase Orders for Flu Treatment from Roche, GSK

RFID and the Future of Pharmaceutical Supply Chains

Gottlieb Challenges Manufacturers to Make Processes More Efficient

Interphex FasterCures Keynote Speaker Stresses Communication and Collaboration

Bayer Bids for Schering AG in Friendly Merger Offer

Fundamentals Stay Strong for Pharma Contract Services Industry

FDA's Risk-based Model Leads to Strategies for Optimizing Site Risk Potential

Merck KGaA Launches Bid For Schering AG

Bush Administration Nominates von Eschenbach to head FDA